Dichloroacetate (DCA)
Sponsors
University of Alberta, AHS Cancer Control Alberta, University of Florida, Jonsson Comprehensive Cancer Center, Saol Therapeutics Inc
Conditions
Congenital Lactic AcidosisGlioblastomaGlioblastoma MultiformeHealthyLung CancerMalignant Gliomas, Glioblastoma MultiformeMetastatic Breast CancerPyruvate Dehydrogenase Complex Deficiency
Phase 1
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
WithdrawnNCT00703859
Start: 2008-07-31Updated: 2016-02-22
A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers
CompletedNCT02690285
Start: 2016-03-01End: 2017-11-01Updated: 2018-12-31
Phase 2
The Safety and Efficacy of DCA for the Treatment of Brain Cancer
CompletedNCT00540176
Start: 2007-10-31End: 2009-08-31Updated: 2014-10-13
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
TerminatedNCT01029925
Start: 2009-12-31End: 2011-11-30Updated: 2016-02-12
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Active, not recruitingNCT05120284
Start: 2022-07-01End: 2026-08-31Target: 40Updated: 2026-06-26